Advertisement

Topics

FDA OKs Nivolumab in Metastatic CRC Subtype

12:05 EDT 1 Aug 2017 | Medscape

The FDA has given accelerated approval to nivolumab for the treatment of microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.
FDA Approvals

Original Article: FDA OKs Nivolumab in Metastatic CRC Subtype

NEXT ARTICLE

More From BioPortfolio on "FDA OKs Nivolumab in Metastatic CRC Subtype"

Quick Search
Advertisement
 

Relevant Topics

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...